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Introduction: Extraskeletal presentation at diagnosis or during the course of multiple myeloma is a rare event. The
prognosis is usually very poor. At the moment there is no agreed gold standard for the treatment of this
presentation.
Case presentation: A 79-year-old Caucasian woman was treated at our hospital for right atrial myeloma
localization. Our patient showed the following signs and symptoms of congestive heart failure: dyspnea,
hypotension, cyanosis and facial edema. Surgery was not considered feasible due to the extent of the disease. Our
patient underwent external-beam radiation therapy using an intensity modulated technique, thus obtaining a
persistent complete remission. Our patient has been in continuous complete local remission for 25 months since
the end of radiotherapy.
Conclusion: The role of radiotherapy is not defined in multiple myeloma with extraskeletal presentation. Our
regimen seems to be effective in controlling the disease in this patient.
This case report adds to the existing literature as it describes an unusual presentation of the disease and a new
therapeutic approach to this rare presentation of multiple myeloma.Introduction
Multiple myeloma (MM) is a malignant disorder of the
plasma cells that is commonly associated with bone mar-
row plasmacytosis and usually restricted only to the
bone marrow. Extraskeletal (ES) localization at diagnosis
or during the course of MM is a rare event with a very
aggressive course. The prognosis is extremely poor, espe-
cially when the diagnosis of ES localization is concurrent
with the diagnosis of MM [1]. Patients presenting with
ES involvement at diagnosis have significantly shorter
progression-free survival compared with other patients
with MM (18 months versus 30 months, P=0.003),
whereas the median overall survival is not statistically
different between the two groups (36 and 43 months, re-
spectively, P=0.36) [2].
Intracardiac localization is extremely rare, with only a
few case reports [2-8].* Correspondence: federica.vigo@tiscali.it
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reproduction in any medium, provided the orWe present the case of a patient with a right atrial
mass that led to signs and symptoms of congestive heart
failure.Case presentation
A healthy 79-year-old Caucasian woman was referred
to our hospital with a diagnosis of stage III immuno-
globulin A-lambda MM with numerous osteolytic areas
(bilateral iliac wings, T3 to T4) and cardiologic symp-
toms of pulmonary embolism. Computed tomography
(CT) of her chest documented the presence of a right
atrial mass (42mm × 53mm), confirmed by subsequent
magnetic resonance imaging (MRI) and fluorine-18-
fluorodeoxyglucose positron emission tomography (F18-
FDG PET). A transesophageal echocardiogram revealed
a large pericardial effusion with evidence of cardiac
tamponade and a large right atrial mass encasing her
interatrial septum and extending into her left atrium.
Histologic specimens of a bone marrow biopsy demon-
strated the presence of tiny aggregates of atypical plasmad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of differentiation 138.
Our patient was treated with four cycles of bortezo-
mib, four cycles of melphalan and prednisone and an-
other four cycles of bortezomib, achieving a lessening of
the symptoms and a stability of the cardiac disease.
Pharmacological toxicity was not significant.
Nine months later, our patient developed a painful
bone relapse. The pain was severe, constant and loca-
lized primarily in her sacrum and the right iliac wing.
The pain increased to some extent with movement. Our
patient received local radiotherapy on both sites
(2000cGy/5 fractions), achieving a reduction in symp-
toms and an improvement of her performance status.Figure 1 Radiographic images of the mass. (A) Computed tomography
fluorodeoxyglucose positron emission tomography confirming this data.One year after the initial diagnosis, our patient pre-
sented to our emergency department because of the new
appearance of signs and symptoms of congestive heart
failure: dyspnea, hypotension, cyanosis and facial edema.
CT of her chest revealed an increase in the size of the
mass (78mm × 84mm), which appeared to infiltrate her
right pulmonary vein and superior vena cava for approxi-
mately 21mm, causing neoplastic thrombosis of her right
subclavian vein (Figure 1A). These findings were confirmed
by echocardiography and F18-FDG PET (Figure 1B).
Restaging examinations documented stable bone disease.
Our patient was evaluated by a surgeon for possible
surgery on her right atrium, but she was considered in-
operable due to the extent of the disease. The diagnosisof the chest documenting the atrial mass; (B) fluorine-18-
Figure 2 Computed tomography of the chest performed one year after the end of radiotherapy. Image describes total disappearance of
the lesion.
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confirmed via examination of a biopsy specimen. In
order to obtain rapid control of the intracardiac disease,
radiation to the cardiac mass was started.
External-beam radiation, totaling 3000cGy in 10 daily
fractions of 300cGy, each with 6mV photons, was deliv-
ered using the intensity modulated radiation therapy
(IMRT) technique.
Our patient was immobilized in the supine position
with a wing board and target localization was accom-
plished using CT simulation. The volumes of interest
were identified on each axial CT slice. The gross tumor
volume was defined as the gross extent of the tumor
shown by imaging (CT, MRI and PET); the clinical target
volume was defined as the gross tumor volume plus a
margin for potential microscopic spread (5mm); and, in
order to account for organ motion and patient setup
errors, the planning target volume was defined by adding
a 1 cm margin to the clinical target volume. Treatment
planning was performed using an inverse planning algo-
rithm in a tomotherapy planning system and our patient
was treated with an IMRT delivered with tomotherapy.
The treatment was generally well tolerated; our patient
showed no symptoms suggestive of radiation-induced tox-
icity. Her symptoms immediately improved with a de-
crease in generalized edema and improved performance
status. A transesophageal echocardiogram performed
three weeks from the end of the radiotherapy confirmed a
significant decrease in tumor size in her right atrium.
Due to our patient’s age and good condition, the medical
staff chose a ‘wait and see’ approach. Three months later,
repeat chest and abdominal CT scans showed complete re-
mission of the cardiac disease, but progressive bone disease.The worsening of the general conditions of our pa-
tient, due to other causes, meant that she was subjected
to supportive care for two months. After the improve-
ment of her health status, our patient started mainten-
ance chemotherapy with lenalidomide and she is
currently tolerating it well.
In a new CT scan of her chest done eighteen months
after the end of the radiotherapy (Figure 2), complete re-
mission of the cardiac disease was confirmed.
Currently, our patient is generally in good condition
and shows no significant cardiac symptoms. Recently
performed chest and abdominal CT documented stabil-
ity of the disease in known locations, but highlighted the
emergence of an axillary mass, for which we are pro-
gramming a new radiation treatment in view of her good
response to previous radiotherapy.
Discussion
There are few previous case reports of intracardiac ma-
lignant plasmacytomas (Table 1); for this reason, experi-
ence with the treatment of this involvement is limited.
Furthermore, in some cases, the diagnosis was made
during autopsy [1,6].
Interestingly, the right atrium seems to be the pre-
dominant location of plasmacytomas involving the heart.
Although its exact etiology is unknown, the presence of
cell surface adhesion molecules on the malignant plasma
cell and their interaction with permissive growth factors
on the endothelial lining of the heart have been consid-
ered as contributing factors [7].
The most optimal therapeutic strategy for intracardiac
malignant plasmacytoma is not well defined. Treatment
options include, when possible, surgical resection or
Table 1 Review of the literature
Reference Extramedullary
localization


































Mitchell et al. [6] Pericardial effusion
and substantial
hypertrophy of the
right and left ventricular
walls, infiltrative
cardiomyopathy
Echocardiogram Bleomycin 20mL in 30mL



















into the pericardial cavity
CR Death from bacterial
pneumonia 182 days
after the first admission
- no autopsy
Champeaux et al. [9] Myocardium and
coronary vessels
Autopsy NR NR Respiratory failure
Owens et al. [10] Pericardial effusion
and large mass





and CT of the heart
Drainage of the effusion,
RT to the heart (30Gy/10fr





Zeiser et al. [11] Pericardial and
pleural effusion
Echocardiography,







Songul et al. [12] Left lobe and
isthmus of thyroid,
bilateral pleural
















Paulus et al. [14] Large pericardial effusion,
large right atrial mass
encasing the interatrial
septum extending into












RT to the cardiac mass
(20Gy/10fr with







in tumor size in the
right atrium and the
aortic root
NR
CT: computed tomography; MRI: magnetic resonance imaging; NR: not reported; RT: radiotherapy; TEE: transesophageal echocardiogram; OK-432 is an
immunomodulator derived from Streptococcus; CR: complete remission.
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or betamethasone with only transitory effects, or radi-
ation therapy (with different doses).
Until now, notwithstanding the wide range of approaches
available, there is no unanimous agreement on the proper
mode of treatment for intracardiac malignant plasmacytoma.
If we analyze the studies reported in Table 1, it is quite
evident how the radiation therapy, in cases in which it was
administered, especially when associated with systemic
therapy [5,10,14], has resulted in a better clinical and in-
strumental response than the other treatments, especially
considering the better toxicity profile of radiation therapy
compared with surgery. Another possible alternative
would seem to be the intrapericardial injection of different
drugs, that, in the few cases reported in literature [5,6,8],
seem to have allowed reasonable local control.
Our patient’s clinical presentation of congestive heart
failure was initially a result of tamponade and also a result
of the anatomic location of the MM in her right atrium. In
this case, the radiation treatment was useful, not only to
reduce the bone pain, but also to decrease the cardiac dis-
ease burden with an immediate improvement in our
patient’s symptoms and performance status.
After a follow-up of 25 months, our patient is alive with
good general condition and she has no limitations to her
daily activities, considering her age and maintenance therapy.
This result leads us to suggest the possibility to obtain
not only control of the symptoms, but also a beneficial
effect in delaying disease progression.
Conclusions
ES tumors are a rare manifestation of MM, with a cu-
mulative incidence of 4.6% of MM cases. The best treat-
ment strategy for these tumors is not yet well defined.
The role of radiotherapy, which is the standard treat-
ment for a solitary plasmacytoma, is much less defined
in MM with ES disease, where radiotherapy is usually
associated with systemic treatment with chemotherapy
or novel agents.
Studies aimed at defining the best therapeutic strategy
for ES MM are needed.
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